natgillin/translations-raw huggingface dataset:
The most commonly reported adverse drug reactions are nasopharyngitis (14.0%), headache (13.6%) and anaemia (13.2%, see section 4.4).
Neželeni učinki zdravila, o katerih so najpogosteje poročali, so nazofaringitis (14,0 %), glavobol (13,6 %) in anemija (13,2 %, glejte poglavje 4.4).
The most commonly reported adverse drug reactions during primary hypercholesterolaemia and mixed dyslipidaemia pivotal trials, at the recommended doses, were nasopharyngitis (4.8%), upper respiratory tract infection (3.2%), back pain (3.1%), arthralgia (2.2%), influenza (2.3%), and nausea (2.1%).
V ključnih preskušanjih pri primarni hiperholesterolemiji in mešani dislipidemiji so bili med uporabo priporočenih odmerkov najpogosteje zabeleženi neželeni učinki nazofaringitis (4,8 %), okužba zgornjih dihal (3,2 %), bolečina v hrbtu (3,1 %), artralgija (2,2 %), gripa (2,3 %) in navzea (2,1 %).
The most commonly reported adverse drug reactions have been diarrhoea, rash, nausea, hypertension, and headache.
Najpogosteje poročani neželeni učinki so bili driska, izpuščaj, navzea, hipertenzija in glavobol.
The most commonly reported adverse event is abdominal pain, occurring in more than 10% of patients in clinical trials.
Neželeni učinek, o katerem so najpogosteje poročali, je bila bolečina v trebuhu, ki se je med kliničnimi preskušanji pojavila pri več kot 10 % bolnic.
The most commonly reported adverse events in patients treated with YENTREVE in clinical trials in SUI and other lower urinary tract disorders were nausea, dry mouth fatigue and constipation.
Neželeni učinki, o katerih so pri bolnicah, zdravljenih z zdravilom YENTREVE v kliničnih preskušanjih o SUI in drugih boleznih spodnjih sečil, najpogosteje poročali, so bili slabost, suha usta, utrujenost in zaprtje.
The most commonly reported adverse reaction during treatment is diarrhoea.
Najbolj pogost zabeležen neželen učinek med zdravljenjem je diareja.
The most commonly reported adverse reaction with Cerdelga is diarrhoea, in approximately 6% of the patients.
Najbolj pogost poročani neželeni učinek zdravila Cerdelga je diareja, ki se pojavi pri približno 6 % bolnikov.
The most commonly reported adverse reactions (occurring in > 10% of patients) are tremor, renal impairment, hyperglycaemic conditions, diabetes mellitus, hyperkalaemia, infections, hypertension and insomnia.
Najpogosteje (pri > 10 % bolnikov) so poročali o neželenih učinkih kot so tremor, okvara ledvic, hiperglikemična stanja, diabetes mellitus, hiperkaliemija, okužbe, hipertenzija in nespečnost.
The most commonly reported adverse reactions (occurring in >10% of patients) are thrombocytopaenia, anaemia, pyrexia, hypertension, hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral oedema, arthralgia, acne, diarrhoea, pain, constipation, nausea, headache, increased blood creatinine, and increased blood lactate dehydrogenase (LDH).
Najpogosteje opisani neželeni učinki (pojavili so se pri  10 % bolnikov) so trombocitopenija, anemija, pireksija, zvišan krvni tlak, hipokaliemija, hipofosfatemija, okužba sečil, hiperholesterolemija, hiperglikemija, hipertrigliceridemija, bolečine v trebuhu, limfokela, periferni edemi, artralgija, akne, diareja, bolečine, zaprtje, navzea, glavobol, zvišanje kreatinina v krvi in zvišanje laktat-dehidrogenaze (LDH) v krvi.
The most commonly reported adverse reactions (occurring in 10% of patients) are thrombocytopaenia, anaemia, pyrexia, hypertension, hypokalaemia, hypophosphataemia, urinary tract infection, hypercholesterolaemia, hyperglycaemia, hypertriglyceridaemia, abdominal pain, lymphocoele, peripheral oedema, arthralgia, acne, diarrhoea, pain, constipation, nausea, headache, increased blood creatinine, and increased blood lactate dehydrogenase (LDH).
Najpogosteje opisani neželeni učinki (pojavili so se pri  10 % bolnikov) so trombocitopenija, anemija, pireksija, zvišan krvni tlak, hipokaliemija, hipofosfatemija, okužba sečil, hiperholesterolemija, hiperglikemija, hipertrigliceridemija, bolečine v trebuhu, limfokela, periferni edemi, artralgija, akne, diareja, bolečine, zaprtje, navzea, glavobol, zvišanje kreatinina v krvi in zvišanje laktat-dehidrogenaze (LDH) v krvi.
The most commonly reported adverse reactions (≥ 20%) among patients treated with both belatacept- based regimens (MI and LI) up to Year 3 are diarrhoea, anaemia, urinary tract infection, peripheral oedema, constipation, hypertension, pyrexia, nausea, graft dysfunction, cough, vomiting, leukopenia, hypophosphataemia, and headache.
Najpogostejši neželeni učinki (≥ 20 %), o katerih so poročali pri bolnikih, ki so se zdravili z belataceptom (BI in MI režim zdravljenja) do 3. leta, so bili: driska, anemija, okužba sečil, periferni edem, zaprtost, hipertenzija, zvišana telesna temperatura, slabost, motnje delovanja presadka, kašelj, bruhanje, levkopenija, hipofosfatemija in glavobol.
The most commonly reported adverse reactions (≥5%) were: nausea, hypersensitivity reactions, infusion site reactions, and headache.
Neželeni učinki, o katerih so poročali najpogosteje (≥ 5 %), so bili: navzea, preobčutljivostne reakcije, reakcije na mestu infundiranja in glavobol.
The most commonly reported adverse reactions are bleedings occurring in total in approximately 14 % of patients treated short-term for elective hip or knee replacement surgery, 16,6 % in patients with atrial fibrillation treated long-term for the prevention of stroke and SEE, and in 14,4 % of patients treated for DVT/PE.
Neželeni učinki, o katerih najpogosteje poročajo, so krvavitve, ki so se skupno pojavile pri približno 14 % bolnikov, ki se kratkotrajno zdravijo v sklopu operativne vstavitve umetnega kolka ali kolena, pri 16,6 % bolnikov z atrijsko fibrilacijo, ki dolgotrajno jemljejo zdravilo za preprečitev možganske kapi in sistemskih emboličnih dogodkov, in pri 14,4 % bolnikov, ki se zdravijo zaradi GVT/PE.
The most commonly reported adverse reactions are gastrointestinal disorders (such as diarrhoea, nausea), nervous system disorders (such as dizziness, headache, somnolence) and fatigue.
Neželeni učinki, o katerih so najpogosteje poročali, so bili gastrointestinalne motnje (kot sta diareja in navzea), bolezni živčevja (kot so omotica, glavobol, somnolenca) in utrujenost.
The most commonly reported adverse reactions are headache and rhinorrhoea.
Neželena učinka, o katerih so poročali najpogosteje, sta glavobol in izcedek iz nosu (rinoreja).
The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache and musculoskeletal pain.
Najpogosteje so spontano poročali o okužbah (kot je nazofaringitis, okužba zgornjih dihal in sinusitis), reakcijah na mestu injiciranja (eritem, srbenje, hemoragija, bolečina ali otekanje), glavobolu in mišično-skeletni bolečini.
The most commonly reported adverse reactions are infections (such as nasopharyngitis, upper respiratory tract infection and sinusitis), injection site reactions (erythema, itching, haemorrhage, pain or swelling), headache and musculoskeletal pain.
Najpogosteje so spontano poročali o okužbah (kot je nazofaringitis, okužbe zgornjih dihal in sinusitis), reakcijah na mestu injiciranja (eritem, srbenje, hemoragija, bolečina ali otekanje), glavobolu in mišično-skeletni bolečini.
The most commonly reported adverse reactions are nausea, experienced by approximately 19% of subjects who received treatment with this medicinal product, headache (20%), and implant site reactions (21%; mainly discolouration, pain, haematoma, erythema).
Neželeni učinki, o katerih so najpogosteje poročali, so navzea, ki se je pojavila pri približno 19 % preizkušancev, ki so prejeli zdravljenje s tem zdravilom, glavobol (20 %) in reakcije na mestu vsaditve (21 %, večinoma sprememba barve, bolečina, hematom, eritem).
The most commonly reported adverse reactions are upper gastrointestinal adverse reactions including abdominal pain, dyspepsia, oesophageal ulcer, dysphagia, abdominal distension and acid regurgitation (> 1 %).
Najbolj pogosto so poročali o neželenih učinkih v zgornjem delu prebavil, vključno z bolečino v trebuhu, dispepsijo, razjedo požiralnika, disfagijo, napetim trebuhom in refluksom kisline (> 1 %).
The most commonly reported adverse reactions as a percent of Colobreathe treated patients were: cough (55%), unpleasant taste (51%), throat irritation (34%), dyspnoea (10%) and dysphonia (10%).
Pri zdravljenju z zdravilom Colobreathe so najpogosteje poročali o naslednjih neželenih učinkih, izraženih v odstotkih: kašelj (55 %), neprijeten okus (51%), draženje žrela, (34 %), dispneja (10 %) in disfonija (10 %).
The most commonly reported adverse reactions during treatment with bortezomib are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
Med zdravljenjem z bortezomibom so najpogosteje poročali o navzei, diareji, zaprtosti, bruhanju, utrujenosti, pireksiji, trombocitopeniji, anemiji, nevtropeniji, periferni nevropatiji (vključno s senzorično nevropatijo), glavobolu, paresteziji, zmanjšanem apetitu, dispneji, izpuščaju, herpesu zostru in mialgiji.
The most commonly reported adverse reactions during treatment with bortezomib are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
Med zdravljenjem z bortezomibom so najpogosteje poročali o slabosti, diareji, zaprtju, bruhanju, utrujenosti, pireksiji, trombocitopeniji, anemiji, nevtropeniji, periferni nevropatiji (vključno s senzorično nevropatijo), glavobolu, paresteziji, zmanjšanem apetitu, dispneji, izpuščaju, herpesu zoster in mialgiji.
The most commonly reported adverse reactions during treatment with VELCADE are nausea, diarrhoea, constipation, vomiting, fatigue, pyrexia, thrombocytopenia, anaemia, neutropenia, peripheral neuropathy (including sensory), headache, paraesthesia, decreased appetite, dyspnoea, rash, herpes zoster and myalgia.
Med zdravljenjem z zdravilom VELCADE so najpogosteje poročali o slabosti, diareji, zaprtju, bruhanju, utrujenosti, pireksiji, trombocitopeniji, anemiji, nevtropeniji, periferni nevropatiji (vključno s senzorično nevropatijo), glavobolu, paresteziji, zmanjšanem apetitu, dispneji, izpuščaju, herpesu zoster in mialgiji.
The most commonly reported adverse reactions following Twinrix Adult administration with the standard 0, 1, 6 month schedule are pain and redness occurring in a per dose frequency of 37.6% and 17.0% respectively.
Po cepljenju s cepivom Twinrix za odrasle po standardni shemi cepljenja 0, 1 in 6 mesecev sta bili najbolj pogosto poročani neželeni reakciji bolečina in rdečina s pogostnostjo 37,6 % in 17,0 % na odmerek.
The most commonly reported adverse reactions following Twinrix Adult administration with the standard 0, 1, 6 month schedule are pain and redness occurring in a per dose frequency of 37.6% and 17.0% respectively.
Po cepljenju s cepivom Twinrix za odrasle po standardni shemi cepljenja 0, 1 in 6 mesecev sta bili najbolj pogosto poročani neželeni reakciji bolečina in rdečina s pogostnostjo 37,6% in 17,0% na odmerek.
The most commonly reported adverse reactions following Twinrix Paediatric administration are pain and redness occurring in a per dose frequency of 28.5% and 11.5% respectively.
Najbolj pogosto poročani neželeni reakciji po cepljenju s cepivom Twinrix za otroke sta bili bolečina in rdečina s pogostnostjo 28,5% in 11,5% na odmerek.
The most commonly reported adverse reactions in clinical studies among sildenafil treated patients were headache, flushing, dyspepsia, nasal congestion, dizziness, nausea, hot flush, visual disturbance, cyanopsia and. vision blurred.
Pri bolnikih zdravljenih s sildenafilom so v kliničnih študijah najpogosteje poročali o naslednjih neželenih učinkih: glavobol, zardevanje, dispepsija, zamašenost nosu, omotica, navzea, vročinski oblivi, motnje vida, cianopsija in zamegljen vid.
The most commonly reported adverse reactions in clinical studies have been blood and lymphatic system disorders including anaemia (45.7%), neutropenia (45.3%) and thrombocytopenia (27%); in general disorders and administration site conditions including fatigue (28.3%), pyrexia (21%) and oedema peripheral (13%); and in infections and infestations including pneumonia (10.7%).
Neželeni učinki, o katerih so v kliničnih študijah najpogosteje poročali, so bile bolezni krvi in limfatičnega sistema, vključno z anemijo (45,7 %), nevtropenijo (45,3 %) in trombocitopenijo (27 %); od splošnih težav in sprememb na mestu aplikacije so poročali o utrujenosti (28,3 %), pireksiji (21 %) in perifernem edemu (13 %); infekcijske in parazitske bolezni so vključevale pljučnico (10,7 %).
The most commonly reported adverse reactions in dialysis-dependent chronic kidney disease (CKD 5D) patients during treatment were discoloured faeces and diarrhoea occurring in 18% and 13% of patients, respectively.
Najpogostejše poročana neželena učinka med zdravljenjem bolnikov s kronično ledvično boleznijo (KLB 5D), odvisno od dialize, sta bila obarvano blato in diareja, ki sta se pojavila pri 18 % oziroma 13 % bolnikov.
The most commonly reported adverse reactions in non-dialysis dependent CKD (CKD ND) patients during treatment were discoloured faeces, constipation and diarrhoea occurring in 27%, 13% and 11% of patients, respectively.
Najpogostejše poročani neželeni učinki med zdravljenjem bolnikov s kronično ledvično boleznijo (KLB ND), neodvisno od dialize, so bili obarvano blato (27 % bolnikov), zaprtost (13 %) in diareja (11 %).
The most commonly reported adverse reactions in patients receiving rivaroxaban were bleedings (see section 4.4. and ‘Description of selected adverse reactions’ below).
Najpogostejši neželeni učinki, o katerih so poročali pri bolnikih, ki so prejemali rivaroksaban, so bile krvavitve (glejte poglavje 4.4 in "Opis izbranih neželenih učinkov" spodaj).
The most commonly reported adverse reactions in patients taking CIALIS for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of CIALIS.
Neželeni učinki, o katerih so pri bolnikih, ki so jemali zdravilo CIALIS za zdravljenje erektilne disfunkcije ali benigne hiperplazije prostate, najpogosteje poročali, so bili glavobol, dispepsija, bolečina v hrbtu in mialgija, pri kateri se incidenca povečuje s povečanjem odmerka zdravila CIALIS.
The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil.
Neželeni učinki, o katerih so pri bolnikih, ki so jemali zdravilo Tadalafil Mylan za zdravljenje erektilne disfunkcije ali benigne hiperplazije prostate, najpogosteje poročali, so bili glavobol, dispepsija, bolečina v hrbtu in mialgija, pri kateri se incidenca povečuje s povečanjem odmerka zdravila Tadalafil Mylan.
The most commonly reported adverse reactions in patients taking tadalafil for the treatment of erectile dysfunction or benign prostatic hyperplasia were headache, dyspepsia, back pain and myalgia, in which the incidences increase with increasing dose of tadalafil.
Neželeni učinki, o katerih so pri bolnikih, ki so jemali zdravilo za zdravljenje erektilne disfunkcije ali benigne hiperplazije prostate, najpogosteje poročali, so bili glavobol, dispepsija, bolečina v hrbtu in mialgija, pri kateri se incidenca povečuje s povečanjem odmerka zdravila Tadalafil Mylan.
The most commonly reported adverse reactions in patients treated with Duloxetine Lilly were nausea, headache, dry mouth, somnolence, and dizziness.
Neželeni učinki, o katerih so pri bolnikih, zdravljenih z zdravilom Duloxetine Lilly, najpogosteje poročali, so bili slabost, glavobol suha usta, zaspanost in omotica.
The most commonly reported adverse reactions in patients treated with FORSTEO are nausea, pain in limb, headache and dizziness.
Najpogosteje poročane neželeni učinki pri bolnikih, zdravljenih z zdravilom FORSTEO, so slabost, bolečine v okončinah, glavobol in omotica.
The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%).
Neželeni učinki, o katerih so v kliničnih študijah faze III najpogosteje poročali, so bile gastrointestinalne (GI) motnje, ki so vključevale drisko (15,7 %) in navzeo (13,9 %).
The most commonly reported adverse reactions occurring in  10% of patients with acromegaly treated with pegvisomant during the clinical trials were headache 25%, arthralgia 16% and diarrhoea 13%.
Najpogosteje opisani neželeni učinki, ki so se v kliničnih preskušanjih pojavili pri  10 % bolnikov z akromegalijo, zdravljenih s pegvisomantom so bili glavobol (25 %), artralgija (16 %) in diareja (13 %).
The most commonly reported adverse reactions of Docetaxel alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Najpogosteje poročani neželeni učinki docetaksela samega so: zmanjšanje števila rdečih ali belih krvnih celic, alopecija, slabost, bruhanje, razjede v ustih, driska in utrujenost.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najpogosteje opisani neţeleni učinki na sam docetaksel so: nevtropenija (ki je bila reverzibilna in ni bila kumulativna; povprečni čas do najmanjšega števila je bil 7 dni, povprečno trajanje hude nevtropenije (< 500 celic/mm3) pa 7 dni), anemija, alopecija, navzeja, bruhanje, stomatitis, driska in astenija.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najpogosteje opisani neţeleni učinki na sam docetaksel so: nevtropenija (ki je bila reverzibilna in ni bila kumulativna; srednji čas do najmanjšega števila je bil 7 dni, srednje trajanje hude nevtropenije (< 500 celic/mm3) pa 7 dni), anemija, alopecija, navzeja, bruhanje, stomatitis, driska in astenija.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najpogosteje opisani neželeni učinki na sam docetaksel so: nevtropenija (ki je bila reverzibilna in ni bila kumulativna; povprečni čas do najmanjšega števila je bil 7 dni, povprečno trajanje hude nevtropenije (< 500 celic/mm3) pa 7 dni), anemija, alopecija, navzeja, bruhanje, stomatitis, driska in astenija.
The most commonly reported adverse reactions of docetaxel alone are: neutropenia (which was reversible and not cumulative; the median day to nadir was 7 days and the median duration of severe neutropenia (<500 cells/mm3) was 7 days), anaemia, alopecia, nausea, vomiting, stomatitis, diarrhoea and asthenia.
Najpogosteje opisani neželeni učinki na sam docetaksel so: nevtropenija (ki je bila reverzibilna in ni bila kumulativna; srednji čas do najmanjšega števila je bil 7 dni, srednje trajanje hude nevtropenije (< 500 celic/mm3) pa 7 dni), anemija, alopecija, navzea, bruhanje, stomatitis, driska in astenija.
The most commonly reported adverse reactions of Docetaxel Winthrop alone are: decrease in the number of red blood cells or white blood cells, alopecia, nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Najpogosteje poročani neželeni učinki zdravila Docetaxel Winthrop samega so: zmanjšanje števila rdečih ali belih krvnih celic, alopecija, slabost, bruhanje, razjede v ustih, driska in utrujenost.
The most commonly reported adverse reactions of severe intensity were diarrhoea (4 subjects, 14%), vomiting (3 patients, 10%), and abdominal distension and ALT increased (2 subjects each, 7%).
Najpogosteje poročani hudi neželeni učinki so bili diareja (4 bolniki, 14 %), bruhanje (3 bolniki, 10 %) in distenzija trebuha ter povišana raven ALT (vsaka od njiju pri 2 bolnikih, 7 %).
The most commonly reported adverse reactions to idebenone are mild to moderate diarrhoea (usually not requiring the discontinuation of the treatment), nasopharyngitis, cough and back pain.
Najpogosteje poročani neželeni učinki idebenona so blaga do zmerna driska (ki navadno ne zahteva prekinitve zdravljenja), nazofaringitis, kašelj in bolečina v hrbtu.
The most commonly reported adverse reactions were abdominal pain and distension (49%), respiratory tract infections (28%), nausea (27%), injection site reactions (21%), headache (17%), vomiting (14%) and oedema peripheral (10%).
Najpogosteje poročani neželeni učinki so bili bolečine v trebuhu in napetost (49 %), okužbe dihal (28 %), navzea (27 %), reakcije na vbodnem mestu (21 %), glavobol (17 %), bruhanje (14 %) in periferni edemi (10 %).
The most commonly reported adverse reactions, occurring in ≥ 10 % of patients in the tadalafil 40 mg treatment arm, were headache, nausea, back pain, dyspepsia, flushing, myalgia, nasopharingitis and pain in extremity.
Neželeni učinki, o katerih so najpogosteje poročali in ki so se pojavili pri več kot 10 % bolnikov, ki so se zdravili s 40 mg tadalafila dnevno, so bili glavobol, slabost, bolečina v hrbtu, dispepsija, zardevanje, mialgija, nazofaringitis in bolečina v udih.
The most commonly reported bleedings (≥4 %) were epistaxis (5.9 %) and gastrointestinal tract haemorrhage (4.2 %).
Krvavitve, o katerih so najpogosteje poročali (≥ 4 %), so bile epistaksa (5,9 %) in krvavitve v prebavilih (4,2 %).
The most commonly reported injection site related adverse reaction was pain (5%); some other injection site adverse reactions reported were (in decreasing frequency): nodule type reactions, erythema type reactions, non-specific injection site reactions, irritation, oedema type reactions, bruising, haemorrhage, and anaesthesia.
Najpogostejši neželeni učinek povezan z mestom injiciranja je bila bolečina (5 %); nekatera druga poročila o neželenih učinkih na mestu injiciranja so (po padajoči pogostnosti): reakcije živčnih vozličkov, eritemske reakcije, nespecifične reakcije na mestu injiciranja, draženje, edemske reakcije, modrice, krvavitve in anestezija.
The most commonly reported liver-related adverse reactions included increases in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and blood bilirubin (see section 4.8).
Neželeni učinki na jetra, o katerih so poročali najpogosteje, so bili zvišanja ravni alanin aminotransferaze (ALT), aspartat aminotransferaze (AST) in ravni bilirubina v krvi (glejte poglavje 4.8).
The most commonly reported reactions are listed in section 4.8. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.
Najpogosteje poročane reakcije so navedene v poglavju 4.8. Navadno so ti simptomi blagi do zmerni, vendar so pri nekaterih bolnikih lahko tudi zelo intenzivni.
The most commonly reported reactions were hyperglycaemia, hypokalaemia, neutropenia, and increased alanine amino transferase (ALT).
Najpogostejše reakcije so bile hipoglikemija, hipokaliemija, nevtropenija in povečana raven alanin-aminotransferaze (ALT).